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Abstract We have generated a novel transgenic
mouse to direct inducible and reversible transgene
expressioninthemelanocyticcompartment.TheDopa-
chrome tautomerase (Dct) control sequences we used
are active early in the development of melanocytes and
so this system was designed to enable the manipulation
of transgene expression during development in utero
and in the melanocyte stem cells as well as mature
melanocytes. We observed inducible lacZ and GFP
reporter transgene activity speciﬁcally in melanocytes
and melanocyte stem cells in mouse skin. This mouse
model will be a useful tool for the pigment cell
community to investigate the contribution of candidate
genes to normal melanocyte and/or melanoma devel-
opment in vivo. Deregulated expression of the proto-
oncogene MYC has been observed in melanoma,
however whether MYC is involved in tumorigenesis
in pigment cells has yet to be directly investigated in
vivo. We have used our system to over-express MYC in
themelanocyticcompartmentandshowfortheﬁrsttime
that increased MYC expression can indeed promote
melanocytic tumor formation.
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Introduction
Despitethedifferencesbetweenmouseandman,theuse
of mouse models to study melanocyte biology and
melanoma has signiﬁcantly contributed to our under-
standing of this ﬁeld (Walker and Hayward 2002).
Melanocytes are pigment-producing cells derived from
the neural crest. They are primarily found in the hair
follicle in adult mouse skin, but are also located in the
epidermisinnon-hairyregionsandthestriavascularisof
the ear and around the eye. Specialized organelles
within melanocytes termed ‘melanosomes’ contain
enzymes that catalyse the multi-step synthesis of
melanin including tyrosinase (Tyr), dopachrome tau-
tomerase(DctorTyrp2)andtyrosinase-relatedprotein1
(Tyrp1). During development, the expression of tran-
scripts encoding these enzymes is spatio-temporally
regulated. Dct is the ﬁrst gene to be expressed from
embryonic day 9 (E9.0) in the presumptive retinal
pigmented epithelium (RPE) of the eye, followed by
expression from E9.5 in the telencephalon and at E10.5
in melanoblasts throughout the embryo after they leave
theneuralcrest(Steeletal.1992;Mackenzieetal.1997;
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DOI 10.1007/s11248-010-9421-6Wilkieetal.2002;Hornyaketal.2001).Incomparison,
Tyr andTyrp1geneexpressionisslightlydelayedinthe
RPE and melanoblasts during development, whilst
expression of all three is maintained in melanocytes in
the adult (Beermann et al. 1992; Steel et al. 1992;
Beermann 1999;M u r i s i e re ta l .2006). In the adult hair
follicle, Tyr protein expression is only detected in non-
proliferating, differentiated melanocytes (Botchkareva
etal.2003)whilstDctproteinexpressionalsomarksthe
melanocyte stem cells (MSC).
The tetracycline regulatory (Tet) system has been
widely used in different mouse models to enable
temporal and site speciﬁc transgene expression,
including models that target the melanocyte compart-
ment (Giuriato et al. 2004; Gimenez et al. 2004;
Yajimaetal.2006).Anelegantexampleofthiswasthe
demonstration of the requirement for expression of an
intiatingoncogenefortumormaintenance,speciﬁcally
HRASV12,inthemelanocyticcompartment(Chinetal.
1999). Unfortunately for melanoma researchers, this
mouse also exhibits transgene expression in the
prostate epithelium (Jeong et al. 2008).
Herewe have used Dct promoter sequences to target
Tet-responsive transgene expression to the mouse
pigment cell compartment, including the MSC popula-
tion. Unlike the other tyrosinase family members, Tyr
and Tyrp1, Dct expression is consistently detected in
melanoma samples, even amelanotic tumors (Orlow
et al. 1995; Pak et al. 2001). Thus the transgenic mouse
line described here will be a useful tool for the pigment
cell community, enabling inducible transgene expres-
sionduringmelanocytedevelopment,inMSCsandtheir
progenyandtoinvestigatethecontributionofcandidate
genes to melanoma in vivo. Furthermore, we have used
this system to over-express MYC in the melanocytic
compartment and show that increased MYC expression
can indeed promote melanocytic tumor formation.
Results and discussion
Mouse Dct promoter sequence directs inducible
reporter gene expression speciﬁcally to melanoma
cells in culture
To produce melanocyte speciﬁc expression of the
reverse-tetracycline transactivator (rtTA) we generated
the construct depicted in Fig. 1 a i. We chose the
rtTA2
S-M2 variant thathas not commonly beenusedin
transgenic mice (Gossen et al. 1995). We reasoned that
this version would be superior to the original rtTA
(as used in the earlier Tyr-rtTA model) because of its
increased sensitivity to doxycycline (dox) and lower
non-speciﬁc activation in the absence of dox (Berens
and Hillen 2003;C h i ne ta l .1999). This construct was
tested for cell-type speciﬁc expression and inducibility
using a Tet-response element (TRE) containing
Luciferase reporter (TRE2-LUC) and results were
replicated using a second TREtight-EGFP reporter
(data not shown). The TRE2-LUC reporter alone was
not responsive to the addition of dox in any cells tested
(Control, Fig. 1 a ii, iii, data not shown). Using a
ubiquitously active promoter (CAAG) to control
rtTA2
S-M2 expression, we observed the very low
background activity of the rtTA2
S-M2 protein in the
absenceofdox,whichissimilartoreporteralonelevels,
and the inducibility of the protein and reporter with the
additionofdox (Fig. 1 a ii, iii).Transfectionofthe Dct/
rtTA2
S-M2 expression construct and treatment of the
cells with dox resulted in the speciﬁc induction of
reportergeneactivityinmelanomacells(D40andB16-
F0),butnotinothernon-melanocyticcelllines(Fig. 1a
ii, iii, data not shown). Thus the Dct/rtTA2
S-M2
construct generates inducible transgene expression
speciﬁcally in cells of the melanocytic lineage.
Generation and selection of Dct/rtTA2
S-M2
transgenic mice
In order to develop a mouse model in which transgene
expression can be manipulated in a tetracycline-
inducible manner in mature melanocytes and the
MSCs, we generated transgenic mice using the Dct/
rtTA2
S-M2 construct (Fig. 1a i). Founder lines were
screened for the presence and maintenance of single-
site integration of the transgene by southern blot
(Fig. 1 b, individual lines referred to as Dct93 and
Dct99). Expression of the rtTA2
S-M2 mRNA by real-
time RT–PCR in samples from whole back and foot
pad skin was detected in Dct93 mice but not control
mice (data not shown).
The Dct promoter selectively drives transgene
expression in the melanocytic compartment
in Dct-rtTA mice
Dct promoter sequences have been used previously
to produce multiple transgenic mouse lines (Zhao
422 Transgenic Res (2011) 20:421–428
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Fig. 1 Generation of a transgenic mouse line for inducible
transgene expression in the pigment cell compartment. a. i,
Schema of the Dct/rtTA2
S-M2 construct, Dopachrome tautom-
erase (Dct) promoter, reverse tetracycline transactivator
rtTA2
S-M2 variant cds and b-globin polyA tail. ii–iii, Lucifer-
ase assays from cells transfected with a TRE2-LUC reporter and
a GFP-expression plasmid (Control), or expression plasmid for
rtTA2
S-M2 under the control of a constitutively active promoter
(pCAAG/rtTA2
S-M2) or the Dct promoter (Dct/rtTA2
S-M2).
Relative luciferase activity was normalized to the reporter with
control transfection in the absence of dox, transfections were
performed in quadruplicate, error bars depict SD. b, southern
blot showing transgenic mouse founder lines Dct93 and Dct99
contain single genomic transgene integration sites, control
(Ctrl) mouse does not contain transgene. c, In sections of the
hair follicle in dorsal (i, ii) and tail (iii) skin, melanoctye stem
cells in the lower permanent portion of the hair follicle (i) and
mature melanocytes in the bulb region of the follicle (ii, iii)
express lacZ in Dct93; TRE-lacZ mice on dox diet. * denotes
endogenous lacZ expression associated with the sebaceous
gland, arrow indicates position of melanocyte stem cell. d, GFP
positive melanocytes are visible in follicular melanocytes in
dorsal skin of Dct93;TRE-H2bGFP mice on dox diet. e, Dct93;
TRE-lacZ mice on dox exhibit lacZ expression in a small
number of cells in the brain, the position is consistent with
rostral migratory stream, and the eye (f). (Scale bars:100 lm)
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123and Overbeek 1999; Pollock et al. 2003; Mackenzie
et al. 1997). The identical Dct promoter fragment
that we use here was incorporated in the commonly
used Dct-lacZ mouse (Mackenzie et al. 1997). The
expression of lacZ has been extensively examined in
the Dct-lacZ mouse and it faithfully recapitulates
endogenous Dct expression in the developing
embryo, with the exception of some unexpected
lacZ expression in the caudal nerves at E10.5
(Mackenzie et al. 1997). We desired transgenic mice
that express the rtTA2
S-M2 protein in the melano-
cytic compartment and that are capable of inducing
expression of TRE-regulated genes in those cells. To
test whether this was the case for any of our mouse
lines, we crossed our founder mice to TRE-lacZ
and TRE-H2BGFP containing mouse reporter lines
(Blanpain et al. 2004; Redfern et al. 1999). In double
transgenic mice fed a dox diet a number of our lines
exhibited lacZ expression in the melanocytes in the
hair follicle by whole mount staining of adult back
and tail skin, that was not observed in control mice
(data not shown). We selected line Dct93 for high
level lacZ expression in melanocytes in adult back
and tail skin and in cells consistent positionally with
the MSCs (Fig. 1 c). Likewise skin samples from
Dct93; TRE-H2bGFP double transgenic mice fed a
dox diet for 7 days contained GFP positive nuclei
within the hair follicle that were not observed in
samples from mice of the same genotype without
dox diet (Fig. 1d, data not shown). The TRE-
H2bGFP reporter mouse line is particularly useful
for ready detection of melanocytic cells and tumors
in which the driver is active.
Apart from expression in follicle melanocytes and
MSC, Dct is also expressed in the mouse brain during
development (Steel et al. 1992; Jiao et al. 2006). We
extended our reporter analysis to include the adult
brain and indeed in the Dct93; TRE-lacZ double
transgenics fed a dox diet we observed a very few
lacZ positive cells in the brain (Fig. 1e). The position
of these cells was consistent with the rostral migra-
tory stream, similar to the observations of Jiao and
colleagues using Dct-lacZ mice. lacZ expression was
also present in the eye of Dct93; TRE-lacZ mice fed
a dox diet. In whole mount the staining appeared in
a limited number of cells approximately positioned
above the ora serrata (Fig. 1f). We did not perform
a more detailed analysis of expression in the brain
or eye.
Mouse Dct93 line can be used to drive oncogene
expression in the melanocytic compartment
to promote melanoma formation
Deregulated expression of the proto-oncogene MYC
has been reported in a wide range of human cancers,
including melanoma (Ricaniadis et al. 2001; Ross
et al. 2006; Greulich et al. 2000).While MYC over-
expression has been observed in human and mouse
models of melanoma, the effect of directed over-
expression of MYC in the melanocytic compartment
in vivo has not been reported. To determine whether
MYC expression is sufﬁcient for tumor formation in
melanocytes in the mouse we crossed the Dct93 line
to TRE-MYC mice (Felsher and Bishop 1999). Dct93
alone and Dct93;TRE-MYC mice were fed a diet
containing dox to promote expression of the MYC
transgene. Of note is the small amount of MYC
expression detected by RT–PCR in whole back skin
samples from mice with the TRE-MYC transgene
alone, suggesting that this TRE-MYC transgene is
partially ‘leaky’ in the skin (Fig. 2 a). This primer/
probe set is speciﬁc for the human MYC expressed
from the transgene and does not recognize endoge-
nous Myc (data not shown). With the addition of dox
to the diet of Dct93;TRE-MYC mice there was a 2.3–
11 fold increase in the amount of MYC mRNA
detected in whole back skin samples (Fig. 2a). Thus,
similar to the reporters (Fig. 1 c, d), the system is
still inducible despite the background MYC trans-
gene ‘leak’. However due to this leak we only
followed cohorts of Dct93 single transgenic animals
and Dct93; TRE-MYC mice all on dox diets and
monitored skin tumor development for at least
18 months.
Melanocytic tumors formed with low penetrance
(only 2 mice out of 26) when MYC was expressed in
Dct93; TRE-MYC mice (on dox, N = 26). This low
incidence of tumor formation was not increased by
neonatal UV irradiation, which has been shown to
promote melanoma development in other mouse
models (Noonan et al. 2001; Hacker et al. 2005;
Broome Powell et al. 1999). The tumors were
nodular, low grade or benign melanocytic tumors
composed of cohesive sheets of melanocytic cells
with epitheloid, ovoid and spindled morphologies
with no obvious epidermal involvement. No melan-
ocytic tumors were observed in Dct93 alone control
mice without MYC expression (on dox, N = 24). The
424 Transgenic Res (2011) 20:421–428
123melanocytic origin of skin tumors was veriﬁed using
a panel of lineage speciﬁc immunohistochemical
markers including S100 and vimentin (Fig. 2 c).
Tumors were negative for pan-keratin (Fig. 2 c). The
speciﬁcity of S100 staining was observed in sections
containing hair follicles with resident hair bulb
melanocytes (Fig. 2 b). Melanocytic tumors were
only found in the tail skin. Expression of MYC was
increased approximately 20-fold in the melanocytic
tumor compared to normal whole skin from the same
individual (Fig. 2a). Similar to a recently reported
melanocytic mouse tumor model, we found no
evidence from sequencing RT–PCR products con-
taining the Braf or Nras coding sequences of non-
synonomous mutations in either cDNA in the
melanocytic tumors analysed (Ohtani et al. 2008).
We report here the generation of a transgenic
mouse line to enable inducible and reversible
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Fig. 2 The Dct93 transgenic mouse line can be used to direct
oncogene expression to the melanocytic compartment to
promote tumor formation, albeit with low penetrance for
MYC. a, Relative MYC expression normalized to GAPDH
levels by RT–PCR in normal back skin (N) or tumor (T) from
mice of the indicated genotypes, each bar represents an
individual mouse. Error bars depict SD. b, Speciﬁc positive
staining (brown) of normal follicular melanocytes in dorsal
mouse skin used as a control for S100 immunohistochemistry,
counter stain is blue. c, Similar to human melanoma, tumors
arising in tail of Dct93; TRE-MYC mice are positive (brown)
for the melanoma antigens, S100 and vimentin and negative for
the epithelial marker, pan-keratin. Bottom row depicts the same
samples just at higher magniﬁcation than the top row. (Scale
bars: 100 lm)
Transgenic Res (2011) 20:421–428 425
123transgene expression in the melanocytic compart-
ment. The Dct control sequences are active early in
the development of melanocytes and so this system
will enable the manipulation of transgene develop-
ment in utero and in the adult, in the melanocytes and
the MSCs. Using this model we have shown that
MYC can act as an oncogene in melanoma develop-
ment. However, we conclude that unlike other tissues
(Felsher and Bishop 1999, Beer et al. 2004; Peleng-
aris et al. 1999; Pelengaris et al. 2002), increased
expression of MYC may not be a potent tumor
initiating event in mouse melanocytes in vivo.
Methods
Plasmid generation
rtTA2
S-M2/rabbit b-globin polyA tail (EcoRI/PstI frag-
ment from pCAGGS-rtTA-S2-M2, B. Welm) was sub-
cloned into similarly digested pBSKS
-. Subsequently
the SalI mouse Dct promoter fragment from pPB2 [the
-3,181 to ?455 fragment as in (Mackenzie et al.
1997)] was inserted into similarly digested pBSKS
-/
rtTA2
S-M2, to produce pBSKS-Dct/rtTA2
S-M2. The
sequence of the construct was veriﬁed, the transgene
contains no introns.
Luciferase reporter assays
Human melanoma cell line D40 (Pavey et al. 2004)
and mouse ﬁbroblast NIH3T3 cells were routinely
maintained in RPMI or DMEM, respectively, with
10% FBS at 37C with 5% CO2. Sub-conﬂuent cells in
24-well trays were transfected with 200 ng pTRE2-
LUC-Puro reporter (Clontech), 50 ng pRLTK internal
control (Promega) and 250 ng expression plasmid per
well (pCX-EGFP control, pCAGG/rtTA2
S-M2 or
pBSKS-Dct/rtTA2
S-M2) with FugeneHD according
to manufacturer’s instructions (Roche). Doxycycline
(2ug/mlﬁnal)wasaddedtowellsafter8 hasspeciﬁed,
cells were harvested36 hafter transfectionandlysates
were analysed for luciferase activity using the Dual
Luciferase Reporter assay (Promega) according to the
manufacturer’s directions. D40 cells are readily
transfectable with a transfection efﬁciency above
40%, as estimated by the number of GFP positive
cells in the control wells.
Generation and screening of transgenic mice
Transgenic mice were generated by the UCSF Trans-
geniccore facilityinthealbinoFVB/Nstrainusingthe
Dct/rtTA2
S-M2/polyA fragment. Mice were initially
screened for the presence of the transgene by PCR
using tail gDNA samples using forward primer
50-CTGGGAGTTGAGCAGCCTAC-30 and reverse
primer 50-GTCTCAGAAGTGGGGGCATA-30. Eight
out of 26 animals were viable, fertile and positive for
the transgene. They and their progeny were further
analysed for single site transgene integration by
Southern blot using a
32P-labelled EcoRI/NdeI frag-
ment from Dct/rtTA2
S-M2. Whole back and tail skin
was dissected from adult double transgenic Dct;
TRE-lacZ or control TRE-lacZ alone mice on dox
and the tissue stained for lacZ expression as per the
manufacturer’s instructions (Chemicon). Samples
were subjected to formaldehyde ﬁxation and parafﬁn
embedding, sectioned and analysed for lacZ positive
cells. lacZ positive cells were not observed in control
mice. Fresh frozen OCT skin sections taken from
control and Dct93; TRE-H2bGFP mice on dox diet for
seven days were counter-stained with Hoechst and
examined for GFP positive nuclei.
Mouse mating and UV irradiation for tumor
studies
Animal experimentation was approved by the Com-
mittee for Animal Research at the University of
California, San Francisco. TRE-MYC (Felsher and
Bishop 1999) (line 36A) mice had been maintained as
heterozygotes for the transgene and backcrossed to
FVB/N for at least 6 generations before crossing to the
Dct93line.Micewereplacedondoxycycline(Doxdiet
pellets, Bio-Serv) containing chow either in utero at
E15 or at weaning. Mice were UV irradiated on post-
natal day 2–5 using 3 cascade-phosphor UV-B lamps
(peak 313 nm, Tyler Research). Exposure time was
calculatedtoprovide4–7 kJ m
2inthesingledosewith
UV dosimeter calibrated for UVB radiation, which
produced noticeable erythema and mild oedema in
some cases. Higher doses [as described in (Noonan
et al. 2001)] were discontinued as particularly at post-
natal day 2–3, such high doses caused excessive
erythema & oedema in this strain and mice had to be
euthanized.Miceweremonitoredfortumorburdenand
euthanized as necessary (Dct93;TRE-MYC mice with
426 Transgenic Res (2011) 20:421–428
123tailtumorswereeuthanizedbetween10and17 months
due to tumor burden) or followed for at least
18 months. Tumors and normal skin samples were
harvestedforFFPEandfreshfrozenforRNAisolation.
RNA isolation, RTPCR and sequencing
Mouse normal skin and tumor samples were homog-
enized in TriReagentLS (Sigma) and total RNA
prepared according to the manufacturers’ instruc-
tions. cDNA synthesis was performed using Super-
scriptII (Invitrogen) and cDNA samples analysed
using real-time PCR for expression of MYC and
GAPDH (Taqman, Applied Biosystems). The relative
expression of MYC compared to GAPDH expression
was determined using the DDCt method (Applied
Biosystems). RT–PCR products covering the entire
coding sequence of Braf and Nras mRNAs were
sequenced from normal and tumor samples.
Immunohistochemistry
FFPE Sects. 4 lm thick were stained for S100 (1:50,
Abcam), vimentin (1:200, Sigma) and pan-keratin
(1:200, Sigma) according to the manufacturer’s
instructions (Vector Labs) with sodium citrate anti-
gen retrieval.Slides were counterstained with Hema-
toxylin Gill#3 (Fisher Scientiﬁc) to produce blue,
nuclear counterstain.
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